Major action on BIVI stock, let's catch up BIVI 4.60 close of 12/6 Rallied to 8 area highs from 3.90 report on Oct 21. We ended up with great data sets on both Alzheimers and Parkinsons. I was on the phone with Life Sci Advisors last night...
A few recent reports first BUYS- BIVI, GANX, MEEC BIVI- Biovie hit a high of 7.70 today from my 3.92 report on Oct 25th. Nearly a double already and it pulled back to 3.60 after my report. I've been buying steady ever since on all dips to...
Had a phone call this morning with MEEC very bullish, notes below the BIVI update BIVI- 5.44 new uptrend high today The stock up from 3.90 report and has potential to get to $40 a share ahead based on the comparative valuation of SAVA and relative data...
Two most recent recommendations are GANX and BIVI. BIVI smashed as high as 4.96 today and I was writing it up around 3.90 a few weeks ago here. Now at 4.62 I am buying more almost every day as I believe the stock can run materially...
RSASF- ReSaas .18, 15 million market cap Currently trading at a fraction of potential business valuation. That is the market we are in right now, but could turn on a dime as most bear markets obviously end at some point. Again, if they get their subscription revenues...
BIVI 3.99 Close of 11/2/22 Some quick notes on Biovie, my most recent recommendation. This is a tough small cap and growth stock market still until the Fed slows down rate hikes, however there are diamonds in the rough. One of which looks like Biovie which...
GANX 3.18- Strong Buy Target remains $11 to $30 potential Market Cap 38 million Cash 33 Million Enterprise Value 5 million This was our last TPS research report in July around $4 a share then. Not much has changed in the story, but what has changed is SIGNIFICANT interest...
BIVI 3.92 area It's time to get back into Biovie. Yes, before you roll your eyes the Biotech sector is bottoming out for one. Also, Biovie has progressed in the clinic which I've been waiting on and now have several value creation catalysts lined up for...
GANX- Gain Therapeutics $4 area Shares outstanding 12 million IPO 2021 at $11 per share Management owns 25%, a few other large players about 15%. Estimated real float about 2 million shares of the 12 million GAIN went public last year at 11, ran to 18 on good news and...
Biotech has turned around after a dismal and unprecedented 16 months of valuation destruction across the board. Multiple small cap and mid cap Biotech stocks are in uptrends now. PCSA remains on our position list and frankly still has massive upside especially if 6422 compound...
indian xxnx horny desi indian cheating slime wife show boobs in webcam.
